To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Higher efficacy and safety of 100 mg BID oral celecoxib in the treatment of knee or hip OA

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
July 2015

Higher efficacy and safety of 100 mg BID oral celecoxib in the treatment of knee or hip OA

Vol: 4| Issue: 7| Number:25| ISSN#: 2564-2537
Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A

Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis

Sci Rep. 2015 May 27;5:10593

Contributing Authors:
C Zeng J Wei H Li T Yang SG Gao YS Li YL Xiong WF Xiao W Luo TB Yang GH Lei

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

24 randomized controlled trials (RCTs) with a total of 11,696 patients were included in this meta-analysis to compare the efficacy and safety of 100 mg BID and 200 mg QD oral celecoxib in the treatment of osteoarthritis (OA) of the knee or hip. Pooled results demonstrated no significant difference between the 200 mg QD and 100 mg BID group in terms of pain intensity and function improvement. Howev...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue